These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17476276)

  • 21. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.
    Larsen TS; Bjerrum OW; Pallisgaard N; Andersen MT; Møller MB; Hasselbalch HC
    Ann Hematol; 2008 Oct; 87(10):847-50. PubMed ID: 18481066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis.
    Chen CC; Chen JL; Lin AJ; Yu LH; Hou HA
    Ann Hematol; 2024 Jun; 103(6):1947-1965. PubMed ID: 38652240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera.
    Khattak SA; Ahmed S; Anwar J; Bozdar M
    J Coll Physicians Surg Pak; 2012 Feb; 22(2):80-3. PubMed ID: 22313642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.
    Grünebach F; Bross-Bach U; Kanz L; Brossart P
    Leukemia; 2006 Dec; 20(12):2210-1. PubMed ID: 17008888
    [No Abstract]   [Full Text] [Related]  

  • 25. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 Mutations are present in all cases of polycythemia vera.
    Wang YL; Vandris K; Jones A; Cross NC; Christos P; Adriano F; Silver RT
    Leukemia; 2008 Jun; 22(6):1289. PubMed ID: 18079740
    [No Abstract]   [Full Text] [Related]  

  • 27. [Polycythemia vera].
    Gemünden C; Gerber B
    Praxis (Bern 1994); 2012 May; 101(10):631-9, 641; quiz 640. PubMed ID: 22565553
    [No Abstract]   [Full Text] [Related]  

  • 28. Mutation screening for JAK2V617F: when to order the test and how to interpret the results.
    Tefferi A; Pardanani A
    Leuk Res; 2006 Jun; 30(6):739-44. PubMed ID: 16460800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?
    Godfrey AL; Nangalia J; Baxter EJ; Massie CE; Kent DG; Papaemmanuil E; Campbell PJ; Green AR
    Blood; 2014 Nov; 124(22):3332-4. PubMed ID: 25414437
    [No Abstract]   [Full Text] [Related]  

  • 30. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.
    Butcher CM; Hahn U; To LB; Gecz J; Wilkins EJ; Scott HS; Bardy PG; D'Andrea RJ
    Leukemia; 2008 Apr; 22(4):870-3. PubMed ID: 17914411
    [No Abstract]   [Full Text] [Related]  

  • 31. Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera.
    Lanikova L; Babosova O; Swierczek S; Wang L; Wheeler DA; Divoky V; Korinek V; Prchal JT
    Blood; 2016 Nov; 128(18):2266-2270. PubMed ID: 27647865
    [No Abstract]   [Full Text] [Related]  

  • 32. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Pieri L; Rotunno G; Gisslinger H; Gisslinger B; Müllauer L; Finazzi G; Carobbio A; Gianatti A; Ruggeri M; Nichele I; D'Amore E; Rambaldi A; Tefferi A
    Blood; 2012 Mar; 119(10):2239-41. PubMed ID: 22246040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
    Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
    Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of busulfan on JAK2V617F allele burden.
    Randi ML; Santarossa C; Peroni E; Cosi E; Duner E; Bertozzi I; Fabris F
    Haematologica; 2014 Mar; 99(3):e44. PubMed ID: 24389308
    [No Abstract]   [Full Text] [Related]  

  • 39. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.
    Larsen TS; Møller MB; de Stricker K; Nørgaard P; Samuelsson J; Marcher C; Andersen MT; Bjerrum OW; Hasselbalch HC
    Hematology; 2009 Dec; 14(6):331-4. PubMed ID: 19941739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.
    Kuriakose ET; Gjoni S; Wang YL; Baumann R; Jones AV; Cross NC; Silver RT
    Haematologica; 2013 Nov; 98(11):e135-7. PubMed ID: 24186314
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.